Twirla Dosage
Apply one Twirla patch weekly for three consecutive weeks (21 days total), followed by one patch-free week, then repeat the cycle 1.
Standard Dosing Regimen
- Each patch delivers: 120 mcg/day levonorgestrel + 30 mcg/day ethinyl estradiol 1
- Application schedule: One patch per week × 3 weeks, then 7 days patch-free 1
- Total cycle length: 28 days (21 days on, 7 days off)
Application Instructions
Approved application sites 1:
- Abdomen
- Buttock
- Upper torso (excluding breasts)
Critical application rules:
- For transdermal use only
- Never cut or alter the patch 1
- Change patch on the same day each week to maintain consistent hormone levels
BMI-Based Prescribing Restrictions
Absolute contraindication: BMI ≥30 kg/m² 1
- Women with BMI ≥30 kg/m² had significantly reduced effectiveness (Pearl Index 8.6 vs 4.3 in women with BMI <30) 2
- Higher risk of venous thromboembolic events in this population 1, 2
Use with caution: BMI 25-29.9 kg/m² 1
- Reduced effectiveness demonstrated in this range
- Consider alternative contraceptive methods 1
Missed or Delayed Patch Management
The CDC guidelines for combined hormonal patches provide clear algorithms 3:
If patch delayed or detached <48 hours:
- Apply new patch immediately
- Keep same patch change day
- No backup contraception needed
- Emergency contraception usually not needed (consider if occurred in first week or last week of previous cycle) 3
If patch delayed or detached ≥48 hours:
- Apply new patch immediately
- Keep same patch change day
- Use backup contraception (condoms) or abstain until patch worn for 7 consecutive days 3
- If occurred during week 3: Skip the patch-free week and start new patch immediately 3
- Consider emergency contraception if: Occurred in first week AND unprotected intercourse in previous 5 days 3
Important Safety Considerations
Absolute contraindications 1:
- Age >35 years who smoke (increased cardiovascular risk)
- BMI ≥30 kg/m²
- High risk of arterial or venous thrombotic disease
- Current or history of breast cancer
- Liver disease (tumors, acute hepatitis, decompensated cirrhosis)
- Undiagnosed abnormal uterine bleeding
- Pregnancy
Common adverse effects (≥2%) 1:
- Application site reactions (unique to transdermal route)
- Nausea (4.1%)
- Headache (3.6%)
- Dysmenorrhea
- Weight gain
Clinical Pearls
The evidence shows Twirla delivers lower steady-state estrogen exposure compared to older patches, equivalent to 30 mcg oral contraceptives 4. This represents an improvement over previous transdermal systems that had higher estrogen exposure and potentially increased VTE risk 5.
Efficacy data: Pearl Index of 4.3 in women with BMI <30 kg/m², comparable to combined oral contraceptives 2, 4. However, efficacy trends downward as BMI increases, making BMI assessment critical before prescribing.
The patch provides autonomy for women who prefer not to take daily pills while maintaining similar efficacy and tolerability to oral contraceptives 5. The once-weekly application improves adherence compared to daily pill-taking.
Stop Twirla at least 4 weeks before major surgery and do not restart until 2 weeks after, due to increased VTE risk 1. Start no earlier than 4 weeks postpartum in non-breastfeeding women 1.